🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT06744322
Recruiting Not applicable

Fast Discharge After Acute Myocardial Infarction Discharge MI

NCT06744322 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2024-12-01
Last updated
2026-03-16

Condition(s) studied

Acute Myocardial Infarction (AMI)

Investigational drug(s) / intervention(s)

Fast discharge strategy

Fast discharge strategy: Patients undergoing invasive management after myocardial infarction will be discharged after 24 (+/- 12) hours.

Study summary

To evaluate the hypothesis that a fast discharge strategy (discharge at 24 \[± 12\] hours) following invasive management for acute myocardial infarction is non-inferior to standard of care (\>36 hours) with respect to the risk of major adverse cardiovascular events (MACE) during follow-up.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Uncomplicated acute myocardial infarction (NSTEMI and STEMI) diagnosed according to the 2023 acute coronary syndrome guidelines of the ESC * Age ≥ 18 years at time of consent * Invasive management strategy and in case of PCI successful intervention of the culprit lesion defined by post-interventional TIMI 3 flow * Ability to understand and willingness to sign and date written informed consent Exclusion Criteria: * Myocardial infarction complicated by cardiac arrest (out-of-hospital cardiac arrest/in-hospital cardiac arrest) * PCI-related complications (coronary perforation, side branch closure, inability to deliver stent/balloon, aortic dissection, allergic reaction grade ≥2, stroke/thromboembolism, access site complications including pseudoaneurysm, arteriovenous fistula, retroperitoneal hemorrhage and arterial dissection/occlusion or emboli) * Malignant arrhythmias including sustained ventricular arrhythmias and persistent bradycardia (\< 50 beats per minute due to sinus node or atrioventricular conduction system abnormalities, second- /third-degree atrioventricular block) after PCI * Ongoing hemodynamic instability (systolic blood pressure \<90 mmHg, elevated lactate concentrations, need for inotropes or vasopressors) * Ongoing respiratory instability defined by Killip class \>I (rales, pulmonary edema) * Ongoing quantitative disorders of consciousness (somnolence, sopor, coma) * Acute kidney injury defined by Kidney Disease Improving Global Outcomes (KDIGO) stages 2 and 3 * Pregnancy * Untreated critical non-culprit lesions requiring revascularization during index hospitalization not allowing fast discharge * Immobility/limited mobility or social circumstances that prevent fast discharge assessed by an interprofessional care team

Primary outcome measure(s)

Trial sites (8)

FacilityCityRegionStatus
Hospital Wiener Neustadt Wiener Neustadt Lower Austria Recruiting
Cardinal Schwarzenberg Hospital Schwarzach Schwarzach im Pongau Schwarzach Im Pongau Not Yet Recruiting
Paracelsus Medical University Salzburg Salzburg State of Salzburg Recruiting
Medical University of Graz Graz Styria Recruiting
Medical University of Innsbruck Innsbruck Tyrol Recruiting
University Teaching Hospital Wels-Grieskirchen Wels Upper Austria Recruiting
Academic Teaching Hospital Feldkirch Feldkirch Vorarlberg Recruiting
Ludwig Maximilian University Munich Munich Bavaria Not Yet Recruiting

More Medical University Innsbruck trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06744322 on ClinicalTrials.gov ↗ ← All trials in Germany